BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23496909)

  • 1. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
    Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
    BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
    Shibamoto Y; Kubota T; Kishii K; Tsujitani M
    Radiother Oncol; 2000 Aug; 56(2):265-70. PubMed ID: 10927148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
    Yahiro T; Masui S; Kubota N; Yamada K; Kobayashi A; Kishii K
    J Radiat Res; 2005 Sep; 46(3):363-72. PubMed ID: 16210793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
    Aoki M; Furusawa Y; Shibamoto Y; Kobayashi A; Tsujitani M
    J Radiat Res; 2002 Jun; 43(2):161-6. PubMed ID: 12238330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.
    Clarke RH; Moosa S; Anzivino M; Wang Y; Floyd DH; Purow BW; Lee KS
    PLoS One; 2014; 9(10):e111199. PubMed ID: 25350400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
    Sheehan J; Cifarelli CP; Dassoulas K; Olson C; Rainey J; Han S
    J Neurosurg; 2010 Aug; 113(2):234-9. PubMed ID: 20001586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
    Kuwabara M; Iida Y; Inanami O; Sawamura S; Yokoyama K; Tsujitani M
    J Radiat Res; 2002 Mar; 43(1):77-88. PubMed ID: 12056332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole
    Yasui H; Kubota N; Nishizumi J; Sakai Y; Yamamori T; Inanami O
    Oncol Lett; 2018 Feb; 15(2):1993-1998. PubMed ID: 29434899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
    Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
    Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
    Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
    BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
    Murata R; Tsujitani M; Horsman MR
    Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
    Matsuoka H; Shibamoto Y; Kubota T; Tsujitani M; Majima T
    Oncol Rep; 2000; 7(1):23-6. PubMed ID: 10601585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals.
    Wang Y; Ying X; Xu H; Yan H; Li X; Tang H
    Int J Nanomedicine; 2017; 12():1369-1384. PubMed ID: 28260885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche.
    Koike N; Kota R; Naito Y; Hayakawa N; Matsuura T; Hishiki T; Onishi N; Fukada J; Suematsu M; Shigematsu N; Saya H; Sampetrean O
    Commun Biol; 2020 Aug; 3(1):450. PubMed ID: 32807853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption.
    Yang W; Barth RF; Carpenter DE; Moeschberger ML; Goodman JH
    Neurosurgery; 1996 May; 38(5):985-92. PubMed ID: 8727825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier.
    Grabb PA; Gilbert MR
    J Neurosurg; 1995 Jun; 82(6):1053-8. PubMed ID: 7760177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine.
    Barth RF; Yang W; Rotaru JH; Moeschberger ML; Boesel CP; Soloway AH; Joel DD; Nawrocky MM; Ono K; Goodman JH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):209-18. PubMed ID: 10758326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response.
    Chu PM; Chiou SH; Su TL; Lee YJ; Chen LH; Chen YW; Yen SH; Chen MT; Chen MH; Shih YH; Tu PH; Ma HI
    Radiat Oncol; 2011 Jan; 6():7. PubMed ID: 21244709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models.
    Leten C; Struys T; Dresselaers T; Himmelreich U
    J Neurooncol; 2014 Sep; 119(2):297-306. PubMed ID: 24990826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
    Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE
    J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.